Marrone Bio Innovations Inc (MBII) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Marrone Bio Innovations Inc (NASDAQ:MBII) in a research report released on Friday.

Several other brokerages have also recently issued reports on MBII. Zacks Investment Research upgraded Marrone Bio Innovations from a sell rating to a hold rating in a research note on Wednesday, January 18th. Jefferies Group LLC reiterated a hold rating and issued a $2.50 price objective on shares of Marrone Bio Innovations in a research note on Tuesday, May 2nd.

Shares of Marrone Bio Innovations (NASDAQ:MBII) opened at 1.35 on Friday. The company’s market capitalization is $33.43 million. Marrone Bio Innovations has a 12-month low of $0.60 and a 12-month high of $2.79. The company has a 50 day moving average price of $1.71 and a 200 day moving average price of $2.06.

Marrone Bio Innovations (NASDAQ:MBII) last announced its earnings results on Wednesday, March 29th. The basic materials company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.06. The company had revenue of $2.69 million during the quarter. Equities analysts anticipate that Marrone Bio Innovations will post ($0.92) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Marrone Bio Innovations Inc (MBII) Rating Reiterated by HC Wainwright” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/05/18/marrone-bio-innovations-inc-mbii-rating-reiterated-by-hc-wainwright.html.

In other news, major shareholder Ardsley Advisory Partners sold 1,189,700 shares of Marrone Bio Innovations stock in a transaction dated Friday, April 28th. The stock was sold at an average price of $1.68, for a total value of $1,998,696.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.25% of the company’s stock.

An institutional investor recently bought a new position in Marrone Bio Innovations stock. Ardsley Advisory Partners bought a new stake in Marrone Bio Innovations Inc (NASDAQ:MBII) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 774,438 shares of the basic materials company’s stock, valued at approximately $1,324,000. Ardsley Advisory Partners owned about 3.15% of Marrone Bio Innovations at the end of the most recent reporting period. Institutional investors own 37.95% of the company’s stock.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

5 Day Chart for NASDAQ:MBII

What are top analysts saying about Marrone Bio Innovations Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Marrone Bio Innovations Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit